Kamel Laribi

High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial

Delphine Rossille, M Gréssier, Diane Damotte et al. · Leukemia · 2014 · 324 citations

Medicine, Hematology, Oncology +14

Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib

David Ghez, Anne Calleja, Caroline Protin et al. · Blood · 2018 · 296 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +14

Zanubrutinib Versus Bendamustine and Rituximab in Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Median 5-Year Follow-Up of SEQUOIA

Mazyar Shadman, Talha Munir, Tadeusz Robak et al. · Journal of Clinical Oncology · 2024 · 57 citations · Full text

Medicine, Oncology, Pharmacotherapy +12

Scedosporiosis/lomentosporiosis observational study (SOS): Clinical significance of <i>Scedosporium</i> species identification

Didier Brönnimann, Dea Garcia‐Hermoso, Françoise Dromer et al. · Medical Mycology · 2020 · 45 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +15

Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell Lymphoma

Nancy L. Bartlett, Uwe Hahn, Won Seog Kim et al. · Journal of Clinical Oncology · 2025 · 39 citations · Full text

Medicine, Hematology, Pharmacotherapy +15